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Background: After total knee replacement, overall blood loss is often underestimated, although it exceeds the
visible blood loss caused by bleeding into the tissues or into the joint. The use of fibrin sealants during surgery has
been suggested to reduce perioperative blood loss and transfusion rates and may be beneficial for patient recovery
and the postoperative function of the joint.
Methods/Design: This will be a single-centre, single-blinded, randomised controlled trial with a parallel design, for
which 68 patients undergoing total knee replacement will be recruited and followed up at 3, 6 and 12 months; 34
will be control patients who will receive the standard orthopaedic surgery treatment (electrocoagulation), and the
other 34 will receive the same treatment plus 5 ml EVICEL™ applied during surgery and used according to the
manufacturer’s instructions. The primary objective is to test the null hypothesis that the effect of EVICEL™ for
controlling haemostasis and reducing postoperative blood loss in patients undergoing total knee replacement is
not superior to the use of electrocoagulation alone. The secondary objective is to show that EVICEL™ reduces the
need for transfusion, increases range of motion, improves clinical outcome and wound healing, and reduces the
need for analgesics. The tertiary objective is to show that EVICEL™ reduces the costs of total knee replacement
treatment.
Discussion: So far, studies on the effect of fibrin sealants in total knee replacement have delivered inconsistent and
ambivalent results, indicating that there is still a need for high-evidence studies as proposed in the presented study
protocol.
Trial registration: German registration number DRKS00007564; date of registration: 26 November 2014.
Keywords: fibrin sealant, EVICEL, total knee arthroplasty, total knee replacement, transfusion rate, haemoglobin loss,
blood loss, range of motionBackground
Implementing a new technology means using a new de-
vice in existing procedures with the global target of im-
proving health care, thereby leading to substantial
improvements in patient outcomes.
In orthopaedic surgery, especially following total hip
and total knee arthroplasty, the overall blood loss is often* Correspondence: stefan.budde@ddh-gruppe.de
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bleeding into the tissues or into the joint [1]. A large loss
of blood means stress to the cardiovascular system and re-
tards the patient’s recovery process [2]. Some patients
undergoing total knee replacement (TKR) require the
transfusion of allogeneic blood products in order to avoid
cardiovascular complications. In addition, a postoperative
haematoma may lead to an impairment of knee range of
motion (ROM) [2].
Since 1972, the supportive use of fibrin sealants in se-
lected surgical procedures has become current practiceticle distributed under the terms of the Creative Commons Attribution License
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surgery. However, the use of fibrin sealants in ortho-
paedic knee and hip surgery, two procedures often asso-
ciated with a considerable amount of postoperative
blood loss, is not considered standard.
EVICEL™ is a fibrin sealant indicated for use as a
supportive treatment in surgery for the improvement
of haemostasis where standard surgical techniques are
insufficient. Bearing in mind that a new orthopaedic
surgery guideline was published recently recommend-
ing that acetylsalicylic acid (aspirin) or clopidogrel
regimens in patients undergoing orthopaedic surgery
not be reduced or interrupted [3], the use of EVICEL™ in
daily clinical practice might contribute to a reduction of
blood loss, especially in these patients. As a consequence
the use of fibrin sealants might improve healing and re-
duce the impaired ROM, leading to less use of analgesics




This study will be a single-centre, parallel-design, ran-
domised controlled trial (RCT) in which 68 patients
undergoing TKR will be recruited according to the in-
clusion/exclusion criteria for RCTs, and treated within
a 12-month period at the Department of Orthopaedic
Surgery. It is registered in the German registry under num-
ber DRKS00007564. Ethical approval has been obtained
from the Institutional Review Board of the Hannover
Medical School under process number ‘6170 M mono’.
The study will be conducted in accordance with the
Helsinki Declaration.
Thirty-four (34) control patients will receive the stand-
ard orthopaedic surgery treatment (electrocoagulation).
Another 34 will receive the same treatment as control
patients plus 5 ml EVICEL™ applied during surgery and
used according to the manufacturer’s instructions.
The main trial period is the stay in hospital for the
surgery and postoperative surveillance. Follow-up exami-
nations of all patients will be conducted 3, 6 and 12
months after surgery. With a recruitment period of 12
months and a follow-up period of 12 months, the total
length of the study period is calculated to be approxi-
mately 24 months.
The study will be terminated when the necessary 34
patients per group have completed the study. Addition-
ally, the sponsor has the right to terminate the study at
any time for reasonable medical or administrative rea-
sons. Also, the principal investigator can decide to ter-
minate the study at any time for reasonable medical or
administrative reasons.
The results manuscript will follow the advice from the
CONSORT guide and its extension to cluster trials.Trial objectives
This randomised controlled study has three main objec-
tives. The primary objective is to test the null hypothesis
that the effect of EVICEL™ on controlling haemostasis
and reducing postoperative blood loss in patients under-
going TKR is no different than with the use of standard
orthopaedic surgery. The secondary objective is to show
that EVICEL™ reduces the need for transfusion and in-
creases ROM when measured 7 days after surgery and in
the long term, improves wound healing and reduces the
need for analgesics. In addition, two clinical outcome
scores will be assessed.
The tertiary objective is to determine the influence of
EVICEL™ use on the overall cost of TKR treatment.Primary and secondary study endpoints
The primary endpoint of this study is postoperative
blood loss after TKR, measured by the difference in
Hb levels at baseline (recorded in the 3 days prior
to randomisation) with respect to the detected mini-
mum in the first 7 days postoperatively and com-
pared between the study group and the control
group. During this period, blood samples will be taken
regularly according to the in-house protocol, and results
will be compared with control values derived from pa-
tients treated under the same conditions but without the
use of EVICEL™. During the operation, all factors that
affect the postoperative level of Hb will be documented.
Secondary endpoints are the need for at least one allo-
geneic blood transfusion or one autologous transfusion,
the ROM of the operated joint, the postoperative use of
analgesics, time until wound healing, clinical outcome
scores, length of hospital stay, and the overall cost of the
treatment.
A follow-up measurement of ROM will be conducted 3,
6 and 12 months after surgery. The ROM of the operated
joint in the study and the control group will be measured
using the angle of maximum flexion. Factors that might in-
fluence the ROM (for example, the use of a peripheral
nerve block) will be documented and might lead to exclu-
sion from the secondary endpoint calculation (for example,
preoperative maximal flexion <90°). The need for at least
one blood transfusion will be compared between the
study and the control group to demonstrate whether
or not EVICEL™ reduces the need for transfusions.
Furthermore, it should be shown that the use of anal-
gesics (according to the WHO pain ladder [4]) can be
reduced by treatment with EVICEL™ and that the
time until the wound is completely dry is shorter. In
addition, it should be shown that the clinical outcome
in the EVICEL™ group is better than that in the con-
trol group. Clinical outcome is assessed by two differ-
ent clinical outcome scores, the clinician-completed Knee
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Injury and Osteoarthritis Outcome Score (KOOS) [5, 6].
For the overall cost of the treatment, differences in
duration of hospital stay, as well as differences in
the total cost of treatment between the two groups
will be compared, including the need for physiother-
apy. The length of the inpatient stay depends not
only on the patient’s condition but also on social
and organisational factors, such as the capacity of
the inpatient rehabilitation centre. Therefore, a the-
oretical discharge date will be defined and evaluated
in addition to the actual date. The theoretical dis-
charge date is defined as the first day on which the
patient achieves the following three criteria: a dry
wound without signs of infection, maximum knee
flexion of at least 90° and the ability to climb stairs
using crutches.
For the sake of safety, patients will be under perman-
ent surveillance during the operation. Adverse events
(AEs) and serious adverse events (SAEs) will be docu-
mented. Clinical signs of infections will be monitored
daily, and blood parameters collected regularly.
Study population
A total of 68 men or nonpregnant women scheduled for
primary unilateral TKR will be recruited and treated in
the context of this RCT.
The inclusion criteria are as follows:
1. Men or women aged from 55 to 70 years on the day
of the operation.
2. Patients with an indication for primary TKR on the
basis of diagnosed osteoarthritis, arthritis or
avascular necrosis.
3. Patients with intact medial and lateral collateral
ligaments (to be diagnosed in the preoperative
examination) who are planned preoperatively to
receive a Stryker Triathlon CR or Triathlon PS
system prosthesis.
4. Patients willing to participate in this RCT and who
have signed the informed consent form approved by
the ethics committee.
The exclusion criteria are as follows:
1. Patients participating in any other clinical trial
within 30 days before inclusion or concurrent with
this study.
2. Pregnant or nursing women.
3. Patients tested positive for HIV, hepatitis B and C.
4. Patients with documented or suspected
hypersensitivity to any of the active substances or
excipients of EVICEL™, or to bone cement or its
components.5. Patients with acute or suspected coagulation
disorders and patients with preoperative blood
parameters INR >1.4 or PTT >40 s.
6. Concomitant medication within 7 days before
surgery with substances that affect haemostasis,
except for low molecular weight heparins or
alternatives in prophylactic dosage indicated for
standard thrombosis prophylaxis.
7. Anaemic patients showing preoperative Hb levels
<11 g/dl.
8. Patients with a deficit in extension >15° or with a
maximal flexion <90°.
9. Highly obese people (BMI >35).
10. Patients suffering from neuromuscular or
neurosensory diseases.
11. Patients with known active tumour disease or
tumour-related diseases.
12. Patients suffering from any significant concurrent
disease, illness or psychiatric disorder that would
compromise their safety or compliance, or interfere
with consent, study participation, follow-up or
interpretation of the results.
13. Patients receiving a prosthesis different from the
Stryker Triathlon CR or Triathlon PS system owing
to intraoperative circumstances (for example, bone
fractures or ligament insufficiencies).
14. Intraoperative deviation from the agreed
haemostatic procedure (for example, use of the
tourniquet deviating from the agreement, for
example in case of surgery lasting >2 h). Patients
with surgery lasting >2 h will not be randomised.Study procedure
On the day of admission eligible patients will be informed
about the study protocol. If they agree to participate in the
study and sign and date the informed consent form, the
following procedure will apply (Table 1):Preoperative examinations (baseline)
The preoperative examinations to establish baseline
measures will include the following:
1. Orthopaedic examination of the lower extremity,
including measurement of ROM, and confirmation
of the medical indication.
2. Blood samples taken and tested according to
in-house protocol. Relevant parameters for the study
are: INR, PTT and complete blood count (CBC)
without differential, including Hb and leucocytes.
The amount of blood needed for this routine
procedure is about 26.5 ml.
3. Subcutaneous injection of certoparin-sodium
(for example, Mono Embolex™) at a dose of
Table 1 Schedule of events
Procedures
Baseline (within 72 h




surgery ± 2 weeks
6 Months after
surgery ± 2 weeks
12 Months after







including use of analgesics
or peripheral nerve block
X X Xd X X X




Coagulation parameters (INR, PTT) X
Treatment application X
Intraoperative data assessment X
Clinical outcome score
assessment (KSS/KOOS)
X Xf X X X
Surgical site assessment Xd X X X
Wound healing assessment Xd
Assessment of patient’s
mobility on crutches (stairs)
Xd




Calculation of overall costs of TKR X
aVirology: Hep B/C and HIV screening
bCBC: Hb, leucocytes
cClinical chemistry: CRP
dAssessment daily during the visits (except for Sundays as for the physical examination)
eAssessment on days 2, 4 and 6 (+/− 1 day) and on day 7
fAssessment on day 7
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evening onwards. An equivalent drug might be used
as an alternative, depending on the guidelines (for
example, no preoperative administration in the
case of some oral products).
The following general data will be collected on the
corresponding case report form (CRF): patient ID;
gender and date of birth; height and weight; BMI;
medical history, especially regarding thromboembolic
events; smoking status; comorbidities and concomi-
tant medications. In addition, the following specific
data will be assessed: indication(s) for TKR, Hb level
(g/dl), C-reactive protein (CRP) (mg/dl), leucocytes
(1/μl), virology (hepatitis B/C and HIV screening),
haemostatic parameters (INR and PTT), ROM (angle
of maximum flexion), details of medications used as
prophylaxis against thrombosis, and assessment of
KSS and KOOS.Details of the operation and of EVICEL™ administration
Investigators will perform the operation according to the
established in-house standard and the guidelines of the
prosthesis manufacturer. The operation will follow a
very strict protocol in order to minimise adverse factors.
The prosthesis implanted will be the Stryker Triathlon™
system. All components are always cemented with
antibiotic-containing cement (Refobacine Palacos). The
operation will be performed in a bloodless field: prior to
the skin incision, the tourniquet is set to 250 mmHg.
During the operation haemostasis will be performed
conventionally by electrocoagulation.
For the study group, haemostasis is extended by the use
of EVICEL™ according to the manufacturer’s guidelines
and recommendations. The application will be performed
by the surgeons themselves. The first application takes
place immediately after lavage, before implanting the
prosthesis: 2 ml of EVICEL™ are sprayed into the popliteal
fossa, which cannot be approached subsequently. Where
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of the prosthesis, EVICEL™ is sprayed on those areas.
After hardening of the bone cement, functional tests and
conventional haemostasis are performed as usual. The
second administration of EVICEL™ is carried out on the
meniscal and capsular blood vessels as well as in the
superior recess (a total of 2 ml). A wait of 2 min without
any action is necessary before starting the suture. After
suturing the joint capsule, 1 ml of EVICEL™ is sprayed
into the subcutaneous tissue. Suction or swabbing must
be strictly avoided in the areas where EVICEL™ has been
administered.
In case of complications occurring during the adminis-
tration of EVICEL™ (for example, intraoperative thrombo-
embolic events or allergic reactions), the application will
be stopped immediately in the subject concerned.
For both groups, a sterile compression bandage is
placed after skin suturing. The tourniquet is then
removed.
In order to ensure better comparability of the results,
no wound drainage system will be used in this study as
the drained volume depends on the hardly reproducible
position of the drainage in situ.
The tourniquet must be removed after 2 h at the
latest. If the operating time from incision to suturing
exceeds 2 h, the tourniquet is removed earlier in the
procedure. In this situation, the patient will be with-
drawn from the study.
The following specific data concerning the operation
are collected: duration of surgery; type of anaesthesia
(spinal or general); management of fluid balance; use of
tourniquet (pressure in mmHg and time in minutes);
amount of EVICEL™ used (ml); intraoperative com-
plications; use of peripheral/nerve blocks; number of
allogeneic and autologous blood units transfused; and
documentation of autologous retransfusion of blood
collected during surgery.
Postoperative procedure
The postoperative procedure is described as follows:
1. Prophylaxis against thrombosis is continued with
certoparin-sodium 3,000 IU (or alternative) once
daily until the patient reaches a physiological level of
activity.
2. The bandages are removed on day 1 after surgery.
Physiological exercises, manual lymphatic drainage and
mobilisation of the patient under full weight-bearing
begin on day 1, according to the established in-house
standard. Sutures are removed between days 10 and 14.
3. The standard postoperative transfusion criterion at
the site is an Hb level <6 g/dl, or in case of values
between 6 and 8 g/dl, more than mild symptoms of
anaemia. However, the criteria are soft and must beadapted according to the patient’s individual
situation and his/her comorbidities, especially any
cardiac comorbidities. The decision for or against a
transfusion is therefore made by the treating
anaesthetist or orthopaedic surgeon, according to
their clinical experience. Thus, the unlikely
possibility of transfusing patients with Hb levels
between 8 and 10 g/dl cannot be completely ruled
out. For each transfusion performed, the reasons will
be documented precisely.
4. Collection of blood parameters, their analysis and
the documentation of the secondary endpoints are
carried out as described in point 6 (Assessment of
Efficacy). The amount of blood taken for each of the
four blood tests is about 8.2 ml.
The following postoperative data are collected in the
corresponding CRF (parameters marked with an asterisk
are also assessed during the follow-up examinations):
1. Blood parameters: Hb level 7 days postoperatively,
CRP, leucocytes
2. In case of blood transfusions: number of units
transfused, date of transfusion, Hb value before
transfusion, reason for transfusion
3. ROM: angle of maximum flexion*
4. Use of analgesics (WHO pain ladder)*
5. Time when nerve block catheter is removed
(if appropriate)
6. Complications (for example, disorders of wound
healing, thromboembolic events, signs of infection,
for example, abnormal redness, swelling, pain, loss
of function, hyperthermia)*
7. Time when the wound is completely dry and any
kind of secretion has ceased
8. Duration of hospital stay
9. KSS and KOOS assessments*
10. Type of rehabilitation after hospital stay (stationary,
ambulant or other)*
11. Number of physiotherapy treatment units after
rehabilitation, including manual lymphatic drainage*
12. Total costs of TKR
13. Theoretical date of discharge (defined in section
‘Primary and Secondary Study Endpoints’)
Statistics
Sample size calculation
Statistical analysis of the published clinical evidence regard-
ing the fibrin sealant QUIXIL, demonstrating its effects in
controlling haemostasis and reducing postoperative blood
loss after TKR, was used as a basis to calculate the number
of patients needed for this RCT. Based on the literature [7],
a sample size estimation for changes in Hb level was made
with the statistical program nQuery Advisor 5.
Budde et al. Trials  (2015) 16:299 Page 6 of 10The estimation assumes the following mean values and
standard deviations (SD) of postoperative decreases in Hb
[7]: 25 g/l (SD 10) (study group) and 37 g/l (SD 12) (con-
trol group). The level of significance is set at P = 0.05 and
a two-sided t-test is performed with equal numbers from
the two groups. With a power of 90 % and an estimated
SD of 15 g/l, the required number of cases is 34 per group.
For this sample size estimation we assumed that the use
of additional information such as baseline Hb levels as
covariates would increase the power of the test.
For a total sample size of 68, approximately 120
patients must be screened because about 40 % of the
eligible patients are expected either not to meet theFig 1 Flow diagram of study participants. The CONSORT flow diagram shoinclusion criteria or not to consent to participate, owing
to inconvenience with the follow-up examinations; not
being randomised due to intraoperative circumstances;
or to drop out for other reasons. Since the primary
endpoint is blood loss during the first 7 days, which is
calculated using routine blood tests during the inpatient
stay, no drop-outs regarding the primary endpoint
should be expected after surgery (Fig. 1).
Statistical methods
The statistical analysis will be carried out at the end of
the study; interim analyses are not intended. However,
the analysis of the primary endpoint may be carried outws the anticipated number of patients from enrolment until analysis
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been assessed. For this analysis, ANCOVA for Hb level
differences baseline with respect to the detected mini-
mum in the first 7 postoperative days for both treatment
groups with adjustment for baseline Hb levels will be
used. If the upper limit of the two-sided 95 % confi-
dence interval (CI) of the difference in means be-
tween EVICEL™ and standard orthopaedic surgery as
estimated from the ANCOVA model is <0, the super-
iority of EVICEL™ will be concluded. Missing values
for Hb observations will be replaced by the last ob-
servation carried forward method (LOCF). If there are
no postoperative Hb values available for a particular
patient, that patient will be recorded as having the
largest decrease in Hb of the control group.
AEs and SAEs will be evaluated descriptively by chi-
squared tests.
For the secondary endpoints, the need for at least one
transfusion will be analysed by odds ratios (OR) together
with 95 % CIs. The ROM and the length of hospital stay
will be analysed by t-tests. The total cost per patient will
be analysed using Wilcoxon’s signed ranks test. Time
until wound healing will be tested by log rank tests.
Secondary and tertiary analyses are exploratory and
will be performed descriptively.
The P values will be assessed descriptively and will be
deemed significant when P <0.05.
The primary analysis will be conducted on the
intention to treat (ITT) population, that is, for all rando-
mised patients. Sensitivity analyses will be performed in
the per-protocol (PP) population, including all patients
who completed the study according to the protocol.
Randomisation/blinding
The process of randomisation is performed centrally by
the Institute for Biometry. A randomisation list is created
and assigns the patients to either the control group or the
study group. When the surgical procedure arrives at the
point at which EVICEL™ treatment has to be performed in
the active group (after conventional haemostasis), the
investigator then initiates the randomisation and queries
the patient’s assignment at the Institute for Biometry by
phone. This procedure allows the statement to be made
that the operation prior to the application of EVICEL™ is
concealed and performed without any bias.
In this RCT, the patients will be blinded but owing to
the nature of the intervention the surgeons clearly can-
not be blinded.
The treating surgeons will conduct the therapy in a
way that complies with the single-blinded design of the
study. In the rare case of a spinal anaesthesia, it will be
ensured that patients will have no opportunity to realise
whether they receive the medicinal product under inves-
tigation (IMP) or not. The medical team involved in theoperation and patient’s care is responsible for keeping
the treatment blinded. The nurses, physiotherapists and
physicians collecting data after surgery will also be
blinded to the treatment allocation.
Subject withdrawal
As the application of EVICEL™ is conducted only at a
single time point in a three-step procedure, subjects
cannot be withdrawn from the IMP treatment. The only
exceptions are complications occurring during the oper-
ation, leading to an immediate cessation of EVICEL™
use.
Patients undergoing a thromboembolic or any other
event demanding anticoagulation that exceeds the stand-
ard prophylaxis measures during the first 7 days after
surgery will be recorded as having the smallest Hb value
before anticoagulation. Patients receiving anticoagulation
during the operation will be recorded as having the
largest Hb difference of the control group. The same
procedure applies to patients receiving any kind of blood
product during or after the operation. Because in nearly
all cases there will be a blood sample collection prior to
a transfusion or to a change in anticoagulation medica-
tion, these patients are expected to account for <1 % of
all patients and will be recorded separately.
The following procedure applies to patients receiving
any kind of blood product or an extended anticoagula-
tion medication during or after the operation. Patients
receiving blood transfusions during the operation but
before randomisation will not be randomised. Patients
receiving blood transfusions during the operation and
after randomisation will be recorded as having the largest
Hb difference of the control group. Patients receiving a
blood transfusion after the operation would require meas-
urement of Hb level before transfusion. Patients deterior-
ating despite transfusion will be recorded as having the
smallest observed Hb level. For each transfusion, the Hb
value at the time of transfusion, the reason for the transfu-
sion (with specification of the symptoms) and the time of
transfusion will be documented precisely.
Patients with an intraoperative deviation from the
agreed haemostatic procedure (use of EVICEL™, electro-
coagulation, or of the tourniquet deviating from the
agreement, e.g. in the case of surgery lasting >2 h) will
not be enrolled. In most cases, it is foreseeable before
randomisation that the operation will probably take longer
than 2 h; therefore, those patients will not be randomised,
and the percentage of subjects not included because of the
duration of surgery is expected to be <1 %.
Insurance
Mandatory patient insurance for this trial according to
AMG § 40 (3) has been obtained. Because of this, any
damage to patient health during the conduct of the
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age of €500,000 per patient. This covers all damage that
may occur to the patient either indirectly or directly as a
result of the study medication or interventions in con-
nection with the RCT.
Overview of the medical product under investigation
EVICEL™ is a fibrin sealant kit consisting of two human
plasma-derived components, human clottable protein con-
taining mainly fibrinogen and fibronectin (component 1),
and human thrombin (component 2), both produced by
Omrix Biopharmaceuticals S.A. [8].
EVICEL™ is a further development of QUIXIL, which
has been approved for marketing in 14 EU countries
since 2003, first in the UK in 1999. One difference be-
tween EVICEL™ and QUIXIL is the final composition of
the fibrinogen component, but the thrombin component
remains the same. The fibrinogen component of QUIXIL
contains the synthetic antifibrinolytic agent tranexamic
acid (TA), which inhibits the degradation of fibrinogen.
However, because TA is potentially neurotoxic QUIXIL is
contraindicated for use in neurosurgery and all proce-
dures where contact with the cerebral spinal fluid (CSF)
and dura mater might occur. By specifically removing
plasminogen the need for stabilisation with TA is
avoided, and EVICEL’s fibrinogen is formulated without
TA. Its protein concentration is 30 to 50 % higher, requir-
ing the submission of a new application for marketing
authorisation.
EVICEL is indicated as an adjunct to haemostasis for
use in patients undergoing surgery, when control of
bleeding by standard surgical techniques (such as su-
tures, ligatures or cautery) is ineffective or impractical.
EVICEL™ is intended for epilesional use only, and the
dosage should always be oriented towards the underlying
clinical needs of the patient. The manufacturer recom-
mends a dosage of 5 ml for TKR.
Risks
The following potential risks may occur when adminis-
tering fibrin sealants:
1. Immunogenicity, hypersensitivity, allergic reaction
and anaphylaxis, and the possible development of
antibodies against components of fibrin sealants.
The risk is markedly increased when fibrin sealants
are used repeatedly or in patients with a known
hypersensitivity to the active substances or to any of
the excipients.
2. Thromboembolic events due to accidental
intravascular administration.
3. Transmission of infections. Standard measures to
prevent infections resulting from the use of
medicinal products prepared from human blood orplasma include the selection of donors, screening of
individual donations and plasma pools for specific
markers of infection, and the inclusion of effective
manufacturing steps for the inactivation/removal of
viruses. The measures taken are considered effective
for enveloped viruses such as HIV, hepatitis C virus
and hepatitis B virus, and for the non-enveloped
hepatitis A virus. The measures taken may be of
limited value against non-enveloped viruses such as
parvovirus B19.
4. Complications related to infections or
thromboembolism, postoperative wound
complications.
5. Tissue adhesion at undesired sites owing to
incorrect product application.
Discussion
The clinical significance of and rationale for the concep-
tion of this study was the fact that after TKR only the
‘visible’ blood loss is usually known, whereas ‘hidden’
blood loss often is underestimated. In a study involving
101 patients undergoing TKR, the hidden blood loss
contributed 49 % to the ‘true’ total blood loss from
bleeding into the tissues or into the joint [1].
A decrease in postoperative Hb levels may be caused by
either intraoperative or postoperative blood loss. EVICEL™
is used at the end of the surgery, so that postoperative
blood loss is the only fraction that might be affected by its
use. Therefore, the study was designed to keep intraopera-
tive blood loss as low as possible in order to provide better
conditions for the effect of the fibrin sealant and to
achieve meaningful results. For this reason, all operations
were planned to be conducted in a bloodless field.
Several clinical studies have shown that the preceding
fibrin sealant, QUIXIL, significantly reduces blood loss
in patients undergoing total hip or total knee replace-
ment [7, 9–11]. In contrast, another study evaluating
blood loss and number of blood transfusions in patients
undergoing TKR could not prove any benefit from the
use of QUIXIL [12]. In a study with 165 patients under-
going TKR, the authors concluded that the use of plate-
let gel and fibrin sealant improves ROM, reduces
hospital stay and may reduce the incidence of arthrofi-
brosis [2]. However, during the planning phase of the
study protocol presented here, there were no data con-
cerning the newer fibrin sealant EVICEL.
Owing to delays in obtaining approval for the study
from the competent national authority associated with
product changes, by the time the study was finally ready
for submission there were several published studies in
the literature evaluating the effects of EVICEL in TKR.
Randelli et al. [13] reported in their RCT that the applica-
tion of EVICEL reduces neither perioperative blood loss
nor the need for allogeneic blood transfusion. Skovgaard
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with fibrin sealant and those treated with placebo was
similar, and that no statistically significant differences
could be seen regarding either swelling, pain, strength of
knee extension or ROM.
In another study [15], however, the results suggested
that transfusion rates in anaemic patients undergoing
TKR were significantly lower than in a control group,
and that the use of EVICEL resulted in a significant
reduction of blood loss. In their meta-analysis, Liu et al.
[16] reported that the use of fibrin sealants in TKR sig-
nificantly reduced total blood loss, drainage blood loss
and haemoglobin loss as well as transfusion rates.
In conclusion, a literature search delivers inconsistent
and ambivalent results indicating that, despite the pres-
ence of comparable studies, there is still a need for high-
evidence studies clarifying the role of fibrin sealants in
TKR, as proposed in the study protocol presented here.
Trial status
This RCT was designed as an investigator-initiated study
for which Hannover Medical School was assumed to be
acting as sponsor. The study was funded by Ethicon
Inc., the parent company of Omrix Biopharmaceuti-
cals, which produces the IMP. A contract was signed
and initial financial support was provided according to
the contract terms, which included approval by the
Independent Ethics Committee. Approval by the na-
tional competent authority was not obtained following
feedback from the European Medicines Agency. When
the issues were resolved, the study was prepared for
resubmission to the national competent authority. How-
ever, in the meantime, ETHICON changed their business
strategy and further funding was withdrawn. Therefore,
the study has not yet started patient recruitment.
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